Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 13.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | Trial Milestone | Phase 1/Phase 2 |
| November 15, 2028 | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease | Trial Milestone | Phase 1 |
| September 15, 2029 | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2032 | Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy | Trial Milestone | Phase 2 |
Track LXEO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open LXEO in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.